Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bausch + Lomb Corporation.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.178 news to hum, and the steady introduction of innovative products across categories. 00:00:06.178 -- 00:00:11.464 Pharmaceuticals was a standout thanks to $84 million in Mibo revenue. 00:00:11.464 -- 00:00:16.490 Mibo growth helped bolster our comprehensive drive portfolio, which is front and 00:00:16.490 -- 00:00:20.755 center for eye care professionals, patients, and consumers. 00:00:20.755 -- 00:00:26.261 Effective selling has also meant more surgeons implanting Invista intraocular lenses, 00:00:26.261 -- 00:00:32.444 helping drive 27% constant currency revenue growth in premium IOLs. 00:00:32.444 -- 00:00:37.751 Our loaded and differentiated pipeline will be on full display in just a few weeks 00:00:37.751 -- 00:00:44.059 at Investor Day. Importantly, the pipeline products we'll highlight aren't aspirational. 00:00:44.059 -- 00:00:49.085 These are clinical stage programs with anticipated launches over the next several 00:00:49.085 -- 00:00:51.085 years. 00:00:51.768 -- 00:00:55.994 Every part of our nearly three-year journey since I returned as CEO has been aligned 00:00:55.994 -- 00:01:00.089 to one or more of three categories you've all become familiar with. 00:01:00.089 -- 00:01:05.335 selling excellence, operational excellence, and disruptive innovation. 00:01:05.335 -- 00:01:08.739 Those aren't optional. They're imperatives. 00:01:08.739 -- 00:01:13.685 While our journey is nowhere near complete, given how far we've come, we've introduced 00:01:13.685 -- 00:01:18.891 a fourth category, financial excellence. This is our opportunity to deliver 00:01:18.891 -- 00:01:23.757 sustained, profitable growth that reflects our real potential. 00:01:23.757 -- 00:01:29.097 We'll show you what that looks like at Investor Day when we share...